World's Best Scientists 2026 revealed!
Award Badge
Immunology
USA
2026

D-Index & Metrics

Immunology

D-Index
142
Citations
70373
World Ranking
153
National Ranking
103

Medicine

D-Index
142
Citations
70390
World Ranking
1570
National Ranking
916

Jeffrey Schlom publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Jeffrey Schlom sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 1,004 publications — 99th percentile

99% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Jeffrey Schlom D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Jeffrey Schlom sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 142 D-Index — 97th percentile

97% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Research.com Recognitions

  • 2026 - Research.com Immunology in United States Leader Award
  • 2025 - Research.com Immunology in United States Leader Award

Overview

Jeffrey Schlom is affiliated with the National Institutes of Health in the United States and has contributed extensively to the fields of Medicine and Immunology and Microbiology. Their research primarily focuses on Oncology, Immunology, Molecular Biology, Pulmonary and Respiratory Medicine, and Biotechnology.

Their work encompasses major topics such as Cancer Immunotherapy and Biomarkers, Immunotherapy and Immune Responses, CAR-T cell therapy research, Prostate Cancer Treatment and Research, Cancer Research and Treatments, Immune Cell Function and Interaction, and Immune cells in cancer.

Frequently published in scientific venues, Schlom has a notable record in the following journals and collections:

  • Regular and Young Investigator Award Abstracts
  • Journal for ImmunoTherapy of Cancer
  • Journal of Clinical Oncology
  • Cancer Research
  • Cancer Immunology Research

Among the frequent co-authors in Schlom's collaborations are James L. Gulley, Renee N. Donahue, Julius Strauss, Jason M. Redman, and Claudia Palena.

Selected recent papers include:

  • Dual targeting of TGF-β and PD-L1 via a bifunctional anti-PD-L1/TGF-βRII agent: status of preclinical and clinical advances, 2020, Journal for ImmunoTherapy of Cancer
  • Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with human papillomavirus-associated malignancies, 2020, Journal for ImmunoTherapy of Cancer
  • Dual inhibition of TGF-β and PD-L1: a novel approach to cancer treatment, 2021, Molecular Oncology
  • PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations, 2020, Journal for ImmunoTherapy of Cancer
  • Therapeutic Vaccines for HPV-Associated Malignancies, 2020, ImmunoTargets and Therapy

Schlom's work often addresses mechanisms related to TGF-β and PD-L1 in cancer immunotherapy, with a focus on developing novel therapeutic strategies that involve immune checkpoint targeting and modulation of the tumor microenvironment.

Best Publications

  • Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy

    Eric A. Reits;James W Hodge;Carla A Herberts;Tom A M Groothuis

  • Inhibition of CD4+25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide

    M. E. Christine Lutsiak;Roshanak T. Semnani;Roberto De Pascalis;Syed V. S. Kashmiri

  • Rapid Tumor Penetration of a Single-Chain Fv and Comparison with Other Immunoglobulin Forms

    Takashi Yokota;Diane E. Milenic;Marc Whitlow;Jeffrey Schlom

  • Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer

    Philip W. Kantoff;Thomas J. Schuetz;Brent A. Blumenstein;L. Michael Glode

  • Grafting of “Abbreviated” Complementarity-Determining Regions Containing Specificity-Determining Residues Essential for Ligand Contact to Engineer a Less Immunogenic Humanized Monoclonal Antibody

    Roberto De Pascalis;Makoto Iwahashi;Midori Tamura;Eduardo A. Padlan

  • A spectrum of monoclonal antibodies reactive with human mammary tumor cells

    D Colcher;P H Hand;M Nuti;J Schlom

  • Generation of Human Cytotoxic T Cells Specific for Human Carcinoembryonic Antigen Epitopes From Patients Immunized With Recombinant Vaccinia-CEA Vaccine

    Tsang Ky;Zaremba S;Nieroda Ca;Zhu Mz

  • Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast tumors.

    Donald Kufe;Giorgio Inghirami;Miyako Abe;Daniel Hayes

  • Distribution of Oncofetal Antigen Tumor-associated Glycoprotein-72 Defined by Monoclonal Antibody B72.3

    Ann Thor;Noriaki Ohuchi;Cheryl A. Szpak;William W. Johnston

  • Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes

    Charlie T. Garnett;Claudia Palena;Mala Chakarborty;Kwong-Yok Tsang

  • Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells.

    Benjamin Boyerinas;Caroline Jochems;Massimo Fantini;Christopher R. Heery

  • Analysis of a Human Tumor-associated Glycoprotein (TAG-72) Identified by Monoclonal Antibody B72.3

    Virginia G. Johnson;Jeffrey Schlom;Andrew J. Paterson;Jeffrey Bennett

  • Construction, Binding Properties, Metabolism, and Tumor Targeting of a Single-Chain Fv Derived from the Pancarcinoma Monoclonal Antibody CC49

    D. E. Milenic;T. Yokota;D. R. Filpula;M. A. J. Finkelman

  • Phase I Study in Advanced Cancer Patients of a Diversified Prime-and-Boost Vaccination Protocol Using Recombinant Vaccinia Virus and Recombinant Nonreplicating Avipox Virus to Elicit Anti–Carcinoembryonic Antigen Immune Responses

    John L. Marshall;Robert J. Hoyer;Mary Ann Toomey;Kristen Faraguna

  • External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing.

    Mala Chakraborty;Scott I. Abrams;C. Norman Coleman;Kevin Camphausen

  • An improved linker for single-chain Fv with reduced aggregation and enhanced proteolytic stability.

    Mare Whitlow;Brian A. Bell;Sheau-Line Feng;David Filpula

  • Synthesis of 1-(p-isothiocyanatobenzyl) derivatives of DTPA and EDTA. Antibody labeling and tumor-imaging studies

    Martin W. Brechbiel;Otto A. Gansow;Robert W. Atcher;Jeffrey Schlom

  • Tumor-infiltrating immune cells and prognosis: the potential link between conventional cancer therapy and immunity.

    Caroline Jochems;Jeffrey Schlom

  • A Phase I Study of Active Immunotherapy with Carcinoembryonic Antigen Peptide (CAP-1)-pulsed, Autologous Human Cultured Dendritic Cells in Patients with Metastatic Malignancies Expressing Carcinoembryonic Antigen

    M. A. Morse;Yuping Deng;D. Coleman;S. Hull

  • In Vivo Tumor Targeting of a Recombinant Single-Chain Antigen-Binding Protein

    David Colcher;Robert Bird;Mario Roselli;Karl D. Hardman

  • Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen.

    Sam Zaremba;Elena Barzaga;Mingzhu Zhu;Nirmolini Soares

Frequent Co-Authors

James L. Gulley
James L. Gulley National Institutes of Health
James W. Hodge
James W. Hodge National Institutes of Health
John W. Greiner
John W. Greiner National Institutes of Health
Kwong Y. Tsang
Kwong Y. Tsang National Institutes of Health
Philip M. Arlen
Philip M. Arlen National Institutes of Health
Seth M. Steinberg
Seth M. Steinberg National Institutes of Health
Diane E. Milenic
Diane E. Milenic National Institutes of Health
Scott I. Abrams
Scott I. Abrams Roswell Park Cancer Institute
Albert F. LoBuglio
Albert F. LoBuglio University of Alabama at Birmingham
Ann D. Thor
Ann D. Thor University of Colorado Anschutz Medical Campus

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in Immunology, exploring related healthcare degrees can open diverse career opportunities. Nursing programs, especially those with a focus on mental health, offer practical routes to apply immunological knowledge in patient care. Many students seek the easy nurse practitioner programs to get into, which can provide a smoother entrance into advanced nursing roles.

Mental health nursing is a growing field with specialized training available through the best online pmhnp programs, which emphasize strong clinical placement rates. These programs can be ideal for candidates balancing work and study while gaining valuable hands-on experience.

Affordability is another crucial consideration. The cheapest psych np programs online offer budget-friendly options without compromising education quality, making them accessible to a wider range of students.

Career outcomes and salary expectations also play a significant role when choosing a pathway. Understanding how much do dnps make can help guide decisions about program choice and specializations, ensuring alignment with long-term financial and professional goals.

Best Scientists Citing Jeffrey Schlom

Trending Scientists

Recently Published Articles